Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
ENSPRYNG Inj Lös 120 mg/ml Fertspr 1 ml
Drug
Enspryng, Injektionslösung zur subkutanen Anwendung
Behandlung von Erwachsenen und Jugendlichen mit Neuromyelitis-Optica-Spektrum-Erkrankungen (NMOSD)
11.99.0. – various
HAM – Human medicine
INLFS – Solution for injection in pre-filled syringe
BT – biological medicines
A – Dispensed once only on prescription by a physician or veterinarian (A)
Z – approved
7/13/2020
7/12/2025
Dosage strength
Enspryng 120 mg, Injektionslösung zur subkutanen Anwendung
Behandlung von Erwachsenen und Jugendlichen mit Neuromyelitis-Optica-Spektrum-Erkrankungen (NMOSD)
01
Z – approved
Package
7680676170011
No information made available
A/R – Authorised / referenced
1 pre-filled syringe(s)
001
Z – approved
Declaration
Component
120 mg satralizumabum
histidinum
acidum asparticum
argininum
poloxamerum 188
aqua ad iniectabile
acidum asparticum
argininum
poloxamerum 188
aqua ad iniectabile
Spezialitätenliste***
SL
-
-
7102.55
None
Yes
10%
No
Authorisation holder
7601001010208
Roche Pharma (Schweiz) AG
Grenzacherstrasse 124
4058 Basel (BS)
Grenzacherstrasse 124
4058 Basel (BS)
Date of revision of the text
3/19/2024
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.